<DOC>
	<DOCNO>NCT02803437</DOCNO>
	<brief_summary>This study Japanese post-marketing surveillance ( PMS ) require regulatory authority . General objective PMS confirm clinical usefulness , especially safety profile drug routine clinical practice .</brief_summary>
	<brief_title>Drug Use Investigation Xofigo , Castration Resistant Prostate Cancer With Bone Metastases</brief_title>
	<detailed_description>This local , non-interventional , multi-center , single-cohort study use primary data patient treat Xofigo indication castration resistant prostate cancer ( CRPC ) bone metastasis . A total 300 patient ( valid safety analysis ) enrol within 18 month . During observation period , safety effectiveness information collect . Since patient 's visit occur routine clinical practice , study protocol define exact referral date visit . The physician record patient data define protocol . The outcome variable primary objective Treatment Emergent Adverse Event ( TEAEs ) Adverse Drug Reaction ( ADRs ) . The outcome variable secondary objective include laboratory finding ( e.g . Alkaline Phosphatase [ ALP ] , bone marker measure ) pain status ( analgesic utility ) . The result study submit Japanese regulatory authority part re-examination package completion re-examination period ( 8 year ) . This study conduct accordance Article 14-4 ( re-examination ) Pharmaceutical Affairs Law , Good Post-marketing Surveillance Practice ministerial ordinance Ministry Health , Labor Welfare Japan .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Patients suffer CRPC bone metastases Patients decision initiate treatment Xofigo make per physician 's routine clinical practice . Xofigo treatment na√Øve Patients treat Xofigo previously Patients participating investigational program intervention outside routine clinical practice</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
</DOC>